Clinical Trials · NCT00376064
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 20
- Start date
- Mar 2006
- Locations
- 16 sites, Germany
- Primary endpoint
- Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)